Company news
Aytu BioPharma, Inc. news in 2021
Aytu BioPharma, Inc.'s news releases, calls and decks from 2021, newest first.
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
December 12, 2021
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
December 7, 2021
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
November 22, 2021
Aytu BioPharma Reports First Quarter 2022 Financial Results
November 14, 2021
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
September 26, 2021
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
September 8, 2021
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
July 26, 2021
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
June 27, 2021
Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
May 11, 2021
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
May 9, 2021
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
April 11, 2021
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer
April 4, 2021
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
March 31, 2021
Aytu BioScience Announces Close of Merger with Neos Therapeutics
March 21, 2021
Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients
March 7, 2021
Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year
February 10, 2021
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
February 9, 2021